459 related articles for article (PubMed ID: 27717529)
1. Individualizing surgical treatment based on tumour response following neoadjuvant therapy in T4 primary rectal cancer.
Denost Q; Kontovounisios C; Rasheed S; Chevalier R; Brasio R; Capdepont M; Rullier E; Tekkis PP
Eur J Surg Oncol; 2017 Jan; 43(1):92-99. PubMed ID: 27717529
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response.
Belluco C; Forlin M; Olivieri M; Cannizzaro R; Canzonieri V; Buonadonna A; Bidoli E; Matrone F; Bertola G; De Paoli A
Ann Surg Oncol; 2016 Dec; 23(13):4302-4309. PubMed ID: 27489059
[TBL] [Abstract][Full Text] [Related]
3. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
[TBL] [Abstract][Full Text] [Related]
5. Efforts to improve local control in rectal cancer compromise survival by the potential morbidity of optimal mesorectal excision.
Laurent C; Nobili S; Rullier A; Vendrely V; Saric J; Rullier E
J Am Coll Surg; 2006 Nov; 203(5):684-91. PubMed ID: 17084330
[TBL] [Abstract][Full Text] [Related]
6. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.
Rullier E; Rouanet P; Tuech JJ; Valverde A; Lelong B; Rivoire M; Faucheron JL; Jafari M; Portier G; Meunier B; Sileznieff I; Prudhomme M; Marchal F; Pocard M; Pezet D; Rullier A; Vendrely V; Denost Q; Asselineau J; Doussau A
Lancet; 2017 Jul; 390(10093):469-479. PubMed ID: 28601342
[TBL] [Abstract][Full Text] [Related]
7. Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer: A Propensity Score Analysis.
Jung SM; Yu CS; Park IJ; Kim TW; Kim JH; Yoon YS; Lim SB; Kim JC
Medicine (Baltimore); 2016 May; 95(20):e3718. PubMed ID: 27196490
[TBL] [Abstract][Full Text] [Related]
8. Comparative Outcomes of Neoadjuvant Treatment Prior to Total Mesorectal Excision and Total Mesorectal Excision Alone in Selected Stage II/III Low and Mid Rectal Cancer.
Kulu Y; Tarantino I; Billeter AT; Diener MK; Schmidt T; Büchler MW; Ulrich A
Ann Surg Oncol; 2016 Jan; 23(1):106-13. PubMed ID: 26305025
[TBL] [Abstract][Full Text] [Related]
9. Anterior resection for rectal cancer with mesorectal excision: a prospective evaluation of 622 patients.
Law WL; Chu KW
Ann Surg; 2004 Aug; 240(2):260-8. PubMed ID: 15273550
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and patterns of failure after surgery for T4 rectal cancer in the beyond total mesorectal excision era.
Peacock O; Waters PS; Bressel M; Lynch AC; Wakeman C; Eglinton T; Koh CE; Lee PJ; Austin KK; Warrier SK; Solomon MJ; Frizelle FA; Heriot AG
Br J Surg; 2019 Nov; 106(12):1685-1696. PubMed ID: 31339561
[TBL] [Abstract][Full Text] [Related]
11. Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure?
Rahbari NN; Ulrich AB; Bruckner T; Münter M; Nickles A; Contin P; Löffler T; Reissfelder C; Koch M; Büchler MW; Weitz J
Ann Surg; 2011 Mar; 253(3):522-33. PubMed ID: 21209587
[TBL] [Abstract][Full Text] [Related]
12. Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer.
Kim JC; Takahashi K; Yu CS; Kim HC; Kim TW; Ryu MH; Kim JH; Mori T
Ann Surg; 2007 Nov; 246(5):754-62. PubMed ID: 17968166
[TBL] [Abstract][Full Text] [Related]
13. Tailored Treatment Strategy for Locally Advanced Rectal Carcinoma Based on the Tumor Response to Induction Chemotherapy: Preliminary Results of the French Phase II Multicenter GRECCAR4 Trial.
Rouanet P; Rullier E; Lelong B; Maingon P; Tuech JJ; Pezet D; Castan F; Nougaret S;
Dis Colon Rectum; 2017 Jul; 60(7):653-663. PubMed ID: 28594714
[TBL] [Abstract][Full Text] [Related]
14. Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
Sclafani F; Brown G; Cunningham D; Rao S; Tekkis P; Tait D; Morano F; Baratelli C; Kalaitzaki E; Rasheed S; Watkins D; Starling N; Wotherspoon A; Chau I
Oncologist; 2017 Jun; 22(6):728-736. PubMed ID: 28476941
[TBL] [Abstract][Full Text] [Related]
15. Local excision after neoadjuvant chemoradiotherapy versus total mesorectal excision: a case-matched study in 110 selected high-risk patients with rectal cancer.
Calmels M; Collard MK; Cazelles A; Frontali A; Maggiori L; Panis Y
Colorectal Dis; 2020 Dec; 22(12):1999-2007. PubMed ID: 32813899
[TBL] [Abstract][Full Text] [Related]
16. Total Mesorectal Excision Versus Local Excision After Favorable Response to Preoperative Chemoradiotherapy in "Early" Clinical T3 Rectal Cancer: A Propensity Score Analysis.
Shin YS; Yu CS; Park JH; Kim JC; Lim SB; Park IJ; Kim TW; Hong YS; Kim KP; Yoon SM; Joo JH; Kim JH
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):136-144. PubMed ID: 28816139
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of Laparoscopic Total Mesorectal Excision with Extended Lateral Pelvic Lymph Node Dissection for Advanced Lower Rectal Cancer after Preoperative Chemoradiotherapy.
Ogura A; Akiyoshi T; Nagasaki T; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Kuroyanagi H
World J Surg; 2017 Mar; 41(3):868-875. PubMed ID: 27730352
[TBL] [Abstract][Full Text] [Related]
19. Factors that influence the adequacy of total mesorectal excision for rectal cancer.
Jeyarajah S; Sutton CD; Miller AS; Hemingway D;
Colorectal Dis; 2007 Nov; 9(9):808-15. PubMed ID: 17441969
[TBL] [Abstract][Full Text] [Related]
20. Long-term prognostic value of mesorectal grading after neoadjuvant chemoradiotherapy for rectal cancer.
Madbouly KM; Hussein AM; Abdelzaher E
Am J Surg; 2014 Sep; 208(3):332-41. PubMed ID: 24581995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
